JP2019520407A5 - - Google Patents

Download PDF

Info

Publication number
JP2019520407A5
JP2019520407A5 JP2019500624A JP2019500624A JP2019520407A5 JP 2019520407 A5 JP2019520407 A5 JP 2019520407A5 JP 2019500624 A JP2019500624 A JP 2019500624A JP 2019500624 A JP2019500624 A JP 2019500624A JP 2019520407 A5 JP2019520407 A5 JP 2019520407A5
Authority
JP
Japan
Prior art keywords
formulation
cochleates
cochleate
cryptococcus
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019500624A
Other languages
English (en)
Japanese (ja)
Other versions
JP6991592B2 (ja
JP2019520407A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/041750 external-priority patent/WO2018013711A1/en
Publication of JP2019520407A publication Critical patent/JP2019520407A/ja
Publication of JP2019520407A5 publication Critical patent/JP2019520407A5/ja
Application granted granted Critical
Publication of JP6991592B2 publication Critical patent/JP6991592B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019500624A 2016-07-12 2017-07-12 中枢神経系送達のためのコクリエート化抗真菌化合物及びクリプトコッカス感染症の治療 Active JP6991592B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662361351P 2016-07-12 2016-07-12
US62/361,351 2016-07-12
US201762513800P 2017-06-01 2017-06-01
US62/513,800 2017-06-01
PCT/US2017/041750 WO2018013711A1 (en) 2016-07-12 2017-07-12 Encochleated antifungal compounds for central nervous system delivery and treatment of cryptococcus infections

Publications (3)

Publication Number Publication Date
JP2019520407A JP2019520407A (ja) 2019-07-18
JP2019520407A5 true JP2019520407A5 (enExample) 2020-05-28
JP6991592B2 JP6991592B2 (ja) 2022-01-12

Family

ID=60952715

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019500624A Active JP6991592B2 (ja) 2016-07-12 2017-07-12 中枢神経系送達のためのコクリエート化抗真菌化合物及びクリプトコッカス感染症の治療

Country Status (8)

Country Link
US (3) US11123295B2 (enExample)
EP (1) EP3484447A4 (enExample)
JP (1) JP6991592B2 (enExample)
KR (2) KR20190029642A (enExample)
CN (2) CN109689028A (enExample)
AU (1) AU2017297402B2 (enExample)
CA (1) CA3027668A1 (enExample)
WO (1) WO2018013711A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150297725A1 (en) 2012-07-30 2015-10-22 Rutgers, The State University Of New Jersey Cochleates made with soy phosphatidylserine
MX2022001871A (es) * 2019-08-13 2022-03-11 Matinas Biopharma Nanotechnologies Inc Metodos de tratamiento de las infecciones por criptococo.
CN118370831A (zh) * 2023-01-20 2024-07-23 中国科学院微生物研究所 肌醇磷脂酰胺合成酶抑制剂与两性霉素b的联合用药及其用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU739591B2 (en) * 1996-08-09 2001-10-18 Buckman Laboratories International, Inc. Treatment of fungal infections using a combination of an anti-fungal compound and an N-alkyl heterocyclic compound
US5837254A (en) * 1996-11-14 1998-11-17 Chen; Yu Method of treating candida and cryptococcus fungal infections by administering gentian
US6153217A (en) 1999-01-22 2000-11-28 Biodelivery Sciences, Inc. Nanocochleate formulations, process of preparation and method of delivery of pharmaceutical agents
AUPQ066399A0 (en) * 1999-05-31 1999-06-24 Fujisawa Pharmaceutical Co., Ltd. Antifungal combination use
JP2003529557A (ja) 2000-01-24 2003-10-07 バイオデリバリー サイエンス インコーポレーテッド コクリエート製剤、その調製方法および生物学的関連分子投与のための用途
US20030219473A1 (en) 2002-03-26 2003-11-27 Leila Zarif Cochleates made with purified soy phosphatidylserine
CA2504329C (en) 2002-11-01 2013-08-20 Biodelivery Sciences International, Inc. Geodate delivery vehicles
US20050013854A1 (en) * 2003-04-09 2005-01-20 Mannino Raphael J. Novel encochleation methods, cochleates and methods of use
WO2004092123A2 (en) 2003-04-10 2004-10-28 Microbia, Inc. Inhibitors of fungal invasion
EP1812555B1 (en) * 2004-10-25 2015-04-22 Cellerant Therapeutics, Inc. Methods of expanding myeloid cell populations and uses thereof
RU2396955C2 (ru) * 2005-04-07 2010-08-20 Тояма Кемикал Ко., Лтд. Фармацевтическая комбинация и способ применения противогрибкового средства в комбинации
CA2613705A1 (en) * 2005-06-29 2007-01-04 The Research Foundation Of State University Of New York Compositions and methods for less immunogenic pr0tein-lip1d complexes
WO2009006311A2 (en) * 2007-06-29 2009-01-08 Wisconsin Alumni Research Foundation Structuring effect of cholesterol in peg-phospholipid micelles, drug delivery of amphotericin b, and combination antifungals
DE102008054431B3 (de) * 2008-12-09 2010-06-17 Pari Pharma Gmbh Aerosoltherapievorrichtung
WO2010091090A1 (en) * 2009-02-03 2010-08-12 Biodelivery Sciences International, Inc. Cochleate compositions and methods of use
WO2012151517A1 (en) 2011-05-05 2012-11-08 Coordinated Program Development, Llc Cochleate compositions and methods of making and using same
US20150297725A1 (en) 2012-07-30 2015-10-22 Rutgers, The State University Of New Jersey Cochleates made with soy phosphatidylserine

Similar Documents

Publication Publication Date Title
CN113767106A (zh) 氧杂氮杂喹唑啉-7(8h)-酮类化合物,其制法与医药上的用途
PH12022550611A1 (en) Brd9 bifunctional degraders and their methods of use
MX2016010213A (es) Formulaciones farmaceuticas novedosas.
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
CN111065639A (zh) 一类细胞周期依赖性激酶的降解剂、其制备方法、药物组合物及其用途
BR112017010439A2 (pt) composto, composição farmacêutica, combinação farmacêutica, kit, métodos para controle de uma doença fúngica em uma planta e para prevenção ou tratamento de doença fúngica em um indivíduo, e, uso de um composto
MY199968A (en) Formulations of an lsd1 inhibitor
CN108026053A8 (zh) 作为mIDH1抑制剂的稠合的咪唑类化合物
JP2016528301A5 (enExample)
MX2014000341A (es) Novedosos derivados de trifluoro-metil-oxadiazol y su uso en el tratamiento de enfermedades.
MX2017010287A (es) Composiciones farmaceuticas que comprenden n-(3,5-dimetoxifenil)-n '-(1-metiletil)-n-[3-(1-metil-1h-pirazol-4-il)quinoxalin-6-il]eta no-1,2-diamina.
NZ708593A (en) Novel pyrazole derivative
MX2021011563A (es) Derivados de 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmaceuticas que los incluyen.
WO2020115555A3 (en) Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia
BR112016022598A8 (pt) composição aerossol farmacêutica na forma de um pó seco para liberação pulmonar, forma de dosagem unitária, pacote farmacêutico, kit e uso
WO2017022962A8 (ko) Ripk 억제제를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물
WO2016109217A3 (en) Btk inhibitors
MY163235A (en) Pharmaceutical preparation containing pyridylaminoacetic acid compound
NZ721500A (en) Use of halogen compounds for the treatment and prevention of heart attack and ischemic injury
CN111868059A (zh) 三氟甲基取代的磺酰胺类选择性bcl-2抑制剂
JP2015502926A5 (enExample)
HK1217495A1 (zh) 治疗活性的作为17β-羟基类固醇脱氢酶抑制剂的17-氮取代雌三烯噻唑衍生物
JP2019520407A5 (enExample)
PH12020552274A1 (en) Formulations of an axl/mer inhibitor
WO2017134685A3 (en) Novel hydrazino compounds as btk inhibitors